Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Apr 1;5(4):529-536.
doi: 10.1001/jamaoncol.2018.5904.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

Christopher J D Wallis  1 , Mohit Butaney  2 , Raj Satkunasivam  3 , Stephen J Freedland  4   5 , Sandip P Patel  6 , Omid Hamid  7 , Sumanta K Pal  8 , Zachary Klaassen  9   10
Affiliations
Meta-Analysis

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

Christopher J D Wallis et al. JAMA Oncol. .

Abstract

Importance: Sex-associated differences in immune response are known, but a meta-analysis suggested men, compared with women, derive greater value from immunotherapy for advanced solid-organ malignant neoplasms. However, methodologic concerns and subsequent trials have placed these results in doubt.

Objective: To perform an updated, comprehensive meta-analysis that assesses the efficacy of immunotherapy in advanced cancers according to patient sex.

Design, setting, and participants: A systematic review of studies (n = 23) indexed in MEDLINE (PubMed), Embase, and Scopus from inception of these databases to October 2, 2018, was conducted. Randomized clinical trials that compared immunotherapy with standard of care in the treatment of advanced solid-organ malignant neoplasms were included if overall survival was reported as an outcome and if data stratified by patient sex were available. Observational studies, editorials, commentaries, review articles, non-peer-reviewed publications, studies that compared various immunotherapy regimens, studies that reported other measures of oncologic response, and studies that reported subgroup analyses for 1 sex only were excluded.

Main outcomes and measures: Overall survival, with a test for heterogeneity between women and men, to assess the null hypothesis that no difference in the survival advantage of immunotherapy exists by patient sex.

Results: This meta-analysis included 23 randomized clinical trials that reported on 9322 men (67.9%) and 4399 women (32.1%); the age of most patients was in the 70s. An overall survival benefit of immunotherapy was found for both men (hazard ratio [HR], 0.75; 95% CI, 0.69-0.81; P < .001) and women (HR, 0.77; 95% CI, 0.67-0.88; P = .002). Random-effects meta-analysis of study-level differences in response to immunotherapy demonstrated no statistically significant difference between the sexes (I2 = 38%; P = .60). Subgroup analyses according to disease site, line of therapy, class of immunotherapy, study methodology, and representation of women recapitulated these findings.

Conclusions and relevance: Stratified analyses demonstrated no statistically significant association of patient sex with the efficacy of immunotherapy in the treatment of advanced cancers using overall survival as the outcome.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Freedland reported receiving grants from Merck outside of the submitted work. Dr Patel reported receiving scientific advisory income from AstraZeneca, BMS, Illumina, Tempus, and Novartis. Dr Patel's university receives research funding from Bristol-Myers Squibb, Eli Lilly, Fate, Incyte, AstraZeneca/MedImmune, Merck, Pfizer, Roche/Genentech, Xcovery, Fate Therapeutics, Genocea, and Iovance. Dr Pal reported receiving personal fees from Genentech, Pfizer, and BMS outside of the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. PRISMA Diagram
IO indicates immunotherapy; OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival.
Figure 2.
Figure 2.. Forest Plot of Association Between Overall Survival and Immunotherapy (IO) and Standard of Care (SOC) Stratified by Patient Sex
HR indicates hazard ratio. aNew studies included in this meta-analysis.
See this image and copyright information in PMC

References

    1. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626-638. doi:10.1038/nri.2016.90 - DOI - PubMed
    1. Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999;283(5406):1277-1278. doi:10.1126/science.283.5406.1277 - DOI - PubMed
    1. vom Steeg LG, Klein SL. SeXX matters in infectious disease pathogenesis. PLoS Pathog. 2016;12(2):e1005374. doi:10.1371/journal.ppat.1005374 - DOI - PMC - PubMed
    1. Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis. 2010;10(5):338-349. doi:10.1016/S1473-3099(10)70049-9 - DOI - PMC - PubMed
    1. Cook MB, Dawsey SM, Freedman ND, et al. . Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1174-1182. doi:10.1158/1055-9965.EPI-08-1118 - DOI - PMC - PubMed

Substances